TNYA News and Press, Tenaya Therapeutics Inc. From 09/15/22

The following slide deck was published by Tenaya Therapeutics, Inc. in conjunction with this event. For further details see: Tenaya Therapeutics (TNYA) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced management...

Tenaya Therapeutics ( NASDAQ: TNYA ) said the U.S. Food and Drug Administration had cleared its application to begin clinical testing of TN-301 to potentially treat heart failure with preserved ejection fraction (HFpEF). ( TNYA ) rose 3.1% before the ...

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced clearance of i...

Tenaya Therapeutics press release ( NASDAQ: TNYA ): Q2 GAAP EPS of -$0.69 beats by $0.07 . cash, cash equivalents and investments in marketable securities were $180.9 million For further details see: Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Received State Licensing to Enable cGMP Manufacturing of Drug Product TN-201 and TN-301 IND Submissions on Track for Second Half 2022 Presented Preclinical Data for Multiple Pipeline Programs and Capsid Engineering Efforts SOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (...

Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with IND Filing on Track for 2H 2022 SOUTH SAN FRANCISCO, Calif., ...

Facility to Provide Clinical Supply of Lead Gene Therapy Programs TN-201 and TN-401 for Planned First-in-Human Studies 94,000 sq. ft. Modular Facility has Initial Production Capacity at the 1000L Scale Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company...

Heart Failure 2022 Presentation Includes Preclinical Data Supporting TN-301 Effect in HFpEF Models TN-301 IND Submission on Track for Second Half of 2022 Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver...

Gainers: NeuroMetrix (NURO) +34%. Millicom International (TIGO) +32%. Grab Holdings (GRAB) +30%. SIGA Technologies (SIGA) +26%. Celyad Oncology (CYAD) +19%. Clene (CLNN) +19%. Applied Blockchain (APLD) +19%. Immunome (IMNM) +18%. BIT Mining (BTCM) +18%. Losers: Companhia Energetica de Minas G...